OBJECTIVE： To investigate chemotherapeutic efficacy and safety of Paclitaxel combined with lobaplatin by interventional embolization for cervical cancer. METHODS： Totally 68 cases of cervical cancer patients selected from our hospital during May 2010-Mar. 2014 were divided into control group and observation group according to therapy plan， with 34 cases in each group. Control group was given Paclitaxel liposome for injection 175 mg/m2 added into 5％ Glucose injection 250 mL， ivgtt+Lobaplatin for injection 80 mg/m2 added into 5％ Glucose injection 250 mL， ivgtt. Observation group was given Paclitaxel liposome for injection 175 mg/m2+Lobaplatin for injection 80 mg/m2+5％ Glucose injection 10 mL via percutaneous catheter after selecting uterine artery and tumor vessel by arterial catheterization arteriography， gelfoam embolization. Both groups were treated in the first day of every treatment course， 21 d as a treatment course， for 3 courses. Clinical efficacies were observed in 2 groups as well as the levels of T lymphocyte subsets （CD4+， CD8+， CD4+/CD8+） before and after treatment. The occurrence of ADR during treatment， local recurrence and metastasis after 2 years， and survival situation were recorded. RESULTS： The total response rate of observatio group （85.29％） was significantly higher than that of control group （61.76％）， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in the levels of CD4+， CD8+ or CD4+/CD8+ between 2 groups （P＞0.05）. After treatment， CD4+ and CD4+/CD8+ of 2 groups were increased significantly， while CD8+ was decreased significantly； above indexes of observation group were improved significantly compared to control group， with statistical significance （P＜0.05）. The survival time of observation group [（22.58±0.61）months] was significantly longer than that of control group [（17.61±1.32）months]， and 2-year survival rate （70.59％） was significantly higher than control group （47.06％）， with statistical significance （P＜0.05）. There were no statistical significance in incidence of disease control， incidence of total ADR and incidence of local recurrence and metastasis between 2 groups （P＞0.05）.  CONCLUSIONS： Paclitaxel combined with lobaplatin by interventional embolization show definite chemotherapeutic efficacy for cervical cancer， and can improve the levels of T lymphocyte subset with good safety.